Previously, we observed that the demethylating agent 5-azacytidine (azaC) induces a constant and limited low frequency of sister chromatid exchange (SCE), seemingly due to a limited number of SCE-prone sites whose expression is related to DNA demethylation. An alternative explanation for the low frequency of SCE induction may be its inefficient incorporation into DNA, as it has a higher incorporation into RNA. The aim of the present work is to determine if the frequency of SCE induction is increased after exposure to 5-aza-2#-deoxycytidine (azadC), a compound with the same mechanism of demethylation as azaC but more efficiently incorporated into DNA. Groups of mice were treated with 2.2, 4.4, 6.6 and 8.8 mmol azadC per kilogram body weight, and the SCE frequency, the mitotic index and the average generation time were determined after two cell division cycles. The doseresponse data of SCE induction showed two components: (i) a dose-dependent increase between 0 and 4.4 mmol and (ii) almost a same level of two SCEs per cell at 4.4 and 8.8 mmol. Although azadC is incorporated more efficiently into DNA, as shown by a lower dose required for a maximal effect, the highest frequency of SCE induction is similar to that observed with azaC. These results indicate that the low incorporation of azaC into DNA seems not to be the factor that limits SCE induction, but the limited number of specific SCE-prone sites in demethylated DNA. Perhaps, there are a restricted number of sites prone to homologous recombination due to DNA demethylation.
Introduction
Sister chromatid exchange (SCE) is the cytogenetic expression of homologous recombination event that occurs between sister chromatids during DNA synthesis (1, 2) and is caused by DNA lesions unrepaired before replication, which are produced by mutagens and carcinogenic agents (3, 4) . Moreover, it has been established that SCE provides a repair mechanism for avoiding such lesions during DNA replication and allows the progression of DNA synthesis (5) . Some evidence indicates that SCE also occurs by genomic demethylation, which is induced by inhibitors of DNA methylation (6) (7) (8) , suggesting a potential association between homologous recombination and epigenetic changes. Thus, the following has been demonstrated: (i) a significant induction of SCE in cells whose DNA is demethylated (8) , (ii) an inverse correlation between DNA methylation reduction and SCE frequency (9) , (iii) an inheritable increase in SCE for several cell divisions in cells carrying demethylated DNA (9, 10) and (iv) a synergistic increase in SCE induction by genotoxic agents, including mitomycin C and ultraviolet light, in demethylated cells (11) .
The azanucleosides 5-azacytidine (azaC) and 5-aza-2#-deoxycytidine (azadC) are demethylating agents whose antineoplastic activity has been effective in epigenetic therapy of myelodysplastic syndromes and acute myeloid leukaemia (12, 13) . Both of these agents cause DNA demethylation after deactivation of the DNA methyltransferase (DNAMtase) enzyme responsible for the DNA methylation (14) .
Prior to the DNA demethylation, these compounds are metabolised to produce the active nucleotide azadC#-5#-triphosphate, which is incorporated into DNA-substituting cytosine (15) . When the methylation of the new strand begins, the DNA-Mtase recognises the azacytosine as a natural substrate and forms an abnormally stable covalent bond in which the enzyme remains trapped constituting a voluminous adducts, suppressing the methylating function. These megaadducts promote cellular events involved in the DNA damage response, causing DNA-Mtase degradation and, consequently, DNA demethylation (16) and the formation of double-strand DNA breaks (17) . These breaks can generate chromosomal aberrations and cytotoxycity (18) , as was demonstrated by the micronucleous formation after azaC treatment in a previous study (19) . In addition, it was observed that the breaks could also originate from fragile chromosome sites rich in G-C pairs, which would be highly demethylated (20) and decondensed due to the azaC incorporation (19) .
Although azaC and azadC inhibit DNA methylation through the same mechanism, they have metabolic differences: azaC is incorporated into DNA at a lower rate than azadC is, due to the fact that the first is incorporated into RNA at an 80-90% rate (21) and interferes with protein synthesis (22) . Moreover, the enzymes that catalyse the conversion of these demethylating agents to the triphosphorylated nucleotide are different, and the ribonucleotide reductase enzyme limits the conversion of 5-aza-ribonucleotides to 5-aza-deoxyribonucleotides (15) .
With respect to SCE-inducing capacity, several in vitro and in vivo studies have demonstrated that exposure to azaC produces a statistically significant increase in SCE at the second cell division after treatment when DNA is already demethylated (8) . SCE increase persists for several cycles of cell division, suggesting an epigenetic change (9, 10) . On the other hand, it was observed in human lymphocytes that azadC, while not increasing the rate of SCE, induces SCE preferentially in the spaces at common fragile sites 1q42 and 19q1 (23) .
In a recent study, in bone marrow cells of mice treated with different doses of azaC, we observed a dose-dependent SCE increase that reached a maximum value of two SCEs per cell, which was unchanging after continuing multiple treatment doses (10) . These results show that azaC induces limited SCE due to its low incorporation into DNA because it is more readily incorporated into RNA and needs to be metabolised to azadC or due to a limited number of demethylated sites prone to SCE induction (10) . With the aim of discerning between these two possibilities, we conducted similar experiments with azadC, which is incorporated into DNA with a greater efficiency. If the low azaC incorporation into DNA is responsible for the limited SCE induction, then the more efficient incorporation of azadC into DNA will produce a greater effect on the frequency of SCE induction.
The objective of the present work is to determine if the SCE induction by azadC, whose incorporation into DNA is very specific, surpasses the previously observed limited SCE induction frequency caused by azaC exposure.
Materials and methods

Experimental design
This work consisted of analysing the SCE frequency in bone marrow cells of animal groups treated with different azadC doses and determining the doseresponse relationship of azadC to SCE induction. This response was then compared with the previously observed response to azaC dose (10) . The SCEs were distinguished using an in vivo method of 5-bromo-2#-deoxyuridine (BrdU) incorporation into DNA (24) . Additionally, the cytotoxic effect of these treatments was evaluated.
Animals
All experiments were conducted using male BALB/c mice 2-3 months in age and weighing 30 g. Mice were maintained in plastic cages bedded in sawdust under controlled temperature (22°C) and dark-light periods (light 7 AM-dark 7 PM). Animals were fed with Purina chow for small rodents and given water ad libitum. Mice were treated and housed in accordance with the Guide for the Care and Use of Laboratory Animals (25) .
Chemicals
BrdU, azadC and colchicine were obtained from Sigma-Aldrich Química S.A. de C.V. (Toluca, México).
Protocol
Mice anaesthetised with ether were intraperitoneally injected with a suspension of BrdU adsorbed to activated charcoal of 250-300 mesh (24) . The BrdU dose was 1.5 mg/g body weight. Doses of azadC, shown in the results section, were dissolved in a balanced saline solution and administered to distinct groups of mice by means of a subcutaneous injection 30 min before BrdU treatment. The doses of azadC were established in accordance to the previously published data (26) . Colchicine in aqueous solution was also administered subcutaneously at a dose of 3.75 mg/kg body weight 22 h after the BrdU injection. Two hours later, the animals were sacrificed by cervical dislocation, their femurs were dissected and the bone marrow was obtained by injecting buffered saline solution into one end of the femur. The resulting cell suspensions were centrifuged at 1500 r.p.m., suspended in 0.075 M KCl and incubated at 37°C for 20 min. After incubation, the cell suspensions were centrifuged again and fixed with three washes of methanol-acetic acid (3:1). Finally, the cell suspensions were dropped onto clean chilled slides.
Differential staining of sister chromatids
The slides were dried for at least 24 h to room temperature and then stained according to the fluorescence plus Giemsa method (27) , which was slightly modified (28) .
Analysis
The SCE frequency per cell was determined by analysing 30 metaphases per mouse with their sister chromatids well differentiated, with some exceptions described in Results. The average generation time (AGT) was established according to Ivett and Tice (29) , scoring the frequency of metaphases in first, second or third division based on the number of cells mentioned in Results. The mitotic index (MI) was determined as the number of metaphases per 1000 cells. The number of cells scored was lower when cell toxicity rose. The slides were coded prior to the analysis. Table I show the cytotoxic effect of azadC, which was estimated in terms of MI and AGT, respectively. The MI data indicate that all doses employed caused a clear reduction in the number of metaphases in comparison with the control group. This reduction is directly proportional to the dose of azadC up to a maximum decrease value (80% at 8.8 lmol).
Statistical method
The statistical significance among groups was determined with the Student's t-test using the Microsoft Excel program for PC.
Results
Cytotoxicity of azadC
With regard to AGT, the samples of at least 100 metaphases per mouse were used for the analysis (30) although were not accomplished for the experimental group treated with 8.8 lmol of azadC. This was due to a dose-dependent reduction of cells in metaphase occurred (Column 7). Data showed a significant lengthening of AGT that is proportional to dose. Both indices (MI and AGT) indicate a clear increase in the cytotoxicity, which is directly proportional to azadC dose. Table I show the frequency of SCEs per cell in both azadC-treated, with different doses, and untreated mice, the latter only receiving BrdU. All doses caused SCE frequencies greater than the control frequency and were statistically significant. Although there was a lack of analysable cells with 8.8 lmol/kg, it was observed that azadC is capable of inducing SCE. The capability of azadC to induce SCE at different doses indicates there are two different rates. The first rate from 0 to 4.4 lmol represents a directly proportional response, and the second, from 4.4 to 8.8 lmol, shows a nearly Statistically significant respect to the control with P , 0.05; n is the mice number analysed.
SCE induction at different doses of azadC Columns 8-10 in
R. Rodríguez-Reyes and P. Morales-Ramírez same response, indicating that higher doses of azadC would not cause an additional increase in the SCE induction. The correlation of results from the three indices-SCE (genotoxicity), MI and AGT (cytotoxicity)-shows that when the SCE frequency reaches the maximum value, the MI reaches the maximum reduction and the AGT has its greatest delay.
Comparison of SCE induction by azaC and azadC
A very similar pattern of SCE induction by azaC and azadC treatments can be inferred from the data in Table II , although the doses employed with each compound were different in approximately one order of magnitude. In both cases, the SCE induction had two components: (i) a directly proportional dose-response ratio at low doses and (ii) a maximum increase of approximately two SCEs per cell with higher doses. Moreover, at high doses of these demethylating agents, the analysis was not possible due their associated cytotoxicity.
The analysis of cytotoxic effect on SCE induction caused by these azanucleosides (Table II) indicates that with doses inducing similar numbers of SCEs, azadC is more cytotoxic than azaC. For example, with analogous doses that produced nearly two SCEs per cell (40 lmol/kg azaC versus 4.4 lmol/kg azadC), azaC treatment caused a minimal difference of MI and AGT with respect to the control, and azadC caused $50% reduction in the MI and an increase in AGT of 2.5 h.
Discussion
The observations of SCE induction by exposure to different demethylating agents, including azaC, azadC, L-ethionine and 9-b-D-arabinofuranosyladenine, and the persistence of SCE through several cell generations, both in vitro (7, 9, 31) and in vivo (10), are evidence of an entailment between SCE induction and DNA demethylation. The study of this entailment may bring new insights into the biological meaning of SCE, which to date has not been completely elucidated. Presently, non-repaired lesions of DNA before replication are accepted as the cause of SCE induction (5) since the homologous recombination permits save the block of DNA replication caused by lesions. However, demethylation does not alter the integrity of DNA; therefore, it is currently difficult to explain SCE formation through DNA demethylation (8) .
However, it has been suggested that the presence of demethylated DNA at the replication fork augments the potential for SCE formation due to the increase of uncorrected mismatches. This situation would be the consequence of the absence of the methylated chain, which acts as the biochemical reference for the enzymes that remove mismatches (8) .
Nevertheless, in a recent study in mouse bone marrow cells, we observed that azaC induced a limited rate of SCE of 2 per cell, and this induction persisted through eight cell division cycles (10) . These results contradict the hypothesis that mismatches would be the cause generating azaC-induced SCE for two reasons: (i) the number of SCEs would not be so restricted and (ii) they would not persist through several cell divisions. Therefore, this low and limited SCE induction lead us to propose that the SCE formation in demethylated DNA does not occur at random but rather in specific CpG sites, which are susceptible to the formation of SCE (10) .
Another possibility is that the cytotoxicity of these demethylating agents determines the limit in the number of lesions compatible with cell survival and susceptibility to SCE formation. However, this scenario does not explain the persistence of these lesions through several cell division cycles.
One explanation for the low rate of SCE produced by azaC might be its low grade of incorporation into DNA, which would limit the induction of molecular events responsible for the SCE formation. Importantly, azaC is preferably incorporated into RNA at a rate of 80-90% of its total incorporation into both DNA and RNA (15) .
The objective of this study was to determine the rate of SCE induction by azadC because it is structurally and functionally similar to azaC, but it incorporates into DNA much more efficiently since its action on this molecule is specific and direct (15) . However, the data for the dose-response indicated that the SCE induction by azadC was also low and reached the same limit as the induction caused by azaC.
Therefore, these results support the hypothesis that the existence of specific demethylated sites is the more probable mechanism for the SCE induction associated with DNA demethylation. Moreover, previous evidence indicating that the fragile sites induced by azadC are spaces in which the SCE is produced with a notably high frequency (23) also supports the existence of discrete sites where the SCE produced by DNA demethylation occurs. These sites represent a small fraction of demethylated sites because evidence has been obtained that these agents cause a reduction $60% of DNA methyl cytosine (9, (32) (33) (34) .
The comparison of the present results with those previously obtained for azaC exposure (10) indicates that a 10 times greater dose of azaC than azadC is required to produce the same SCE frequency, suggesting that there was a major efficiency of azadC incorporation into DNA, agreeing with the data that previously reported that the incorporation rate of azaC into DNA is 10 times less than its incorporation into RNA (21) . This might indicate that both azanucleosides reach a similar maximum incorporation into DNA, a point at which they produce the same demethylation grade and, consequently, the same frequency of SCE.
However, the minimal dose at which azadC already induces SCE is much more toxic than the equivalent dose of azaC. This could be explained by the production of a large quantity of mega-adducts, which are the lesions directly associated with the azanucleosides cytotoxicity (16, 35) and whose number probably exceeds the repair capacity, thereby inducing the cell death response.
The results obtained in the present study indicate that the incorporation efficiency of these azanucleosides into DNA is not the factor that limits their SCE-inducing capacity. 
SCE by 5-aza-2#-deoxycytidine
Therefore, we do not reject our previously proposed hypothesis that azanucleosides demethylation causes the epigenetic production of a limited number of SCE-prone sites.
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